Metabolon Collaborates with GSK for Metabolomics Research Platform
By LabMedica International staff writers Posted on 02 Jun 2014 |
Metabolon, Inc. (Research Triangle Park, NC, USA), a diagnostics and research services company offering metabolomics research platforms, has entered into a collaboration with GlaxoSmithKline (GSK; London, UK) to provide metabolomic profiling services and to collaborate on other research projects utilizing Metabolon’s DiscoveryHD4 platform.
The collaboration will give GSK access to Metabolon’s bioinformatics tools in addition to the company’s proprietary disease ontologies, as well as visualization tools that will integrate metabolomics data with existing genomics and proteomics data.
John Ryals, Metabolon president and CEO, commented, “We are pleased to announce a collaboration with GSK. We believe that embedding metabolomic profiling capabilities at the various stages of R&D is important to enhance the phenotypic ‘picture’ with the aim of yielding translatable, meaningful results. Gaps of knowledge can be bridged through the understanding metabolomics provides, which could lead to better targets, higher quality molecules, faster time to the clinic, and reduced risk and cost.”
Metabolomics has conducted thousands of metabolomics studies across numerous therapeutic areas and has developed expertise in metabolic pathways and targets that are involved in the onset of disease and its progression. Metabolon’s technology platforms are known for their rapid, repeatable results. Expert, credentialed biochemists interpret biologic data to provide actionable understanding into key disease metabolic processes, drug action, and patient response.
Metabolomics is a rapidly evolving field of biochemical research and discovery focused on the measurement of small molecules involved in metabolism. Metabolon’s proprietary metabolomics technology maps these small molecule pathways to identify diseases, discover biomarkers, and better understand complex biologic processes. The company’s business uses its metabolomics technology to conduct sponsored studies for life sciences researchers in industry and academia, which provide clues into complex biochemical processes. Data from these studies are used to populate Metabolon’s large and growing metabolomic information and pathway knowledge databases, which generate new product concepts for the company’s diagnostics business.
Related Links:
Metabolon
GlaxoSmithKline
The collaboration will give GSK access to Metabolon’s bioinformatics tools in addition to the company’s proprietary disease ontologies, as well as visualization tools that will integrate metabolomics data with existing genomics and proteomics data.
John Ryals, Metabolon president and CEO, commented, “We are pleased to announce a collaboration with GSK. We believe that embedding metabolomic profiling capabilities at the various stages of R&D is important to enhance the phenotypic ‘picture’ with the aim of yielding translatable, meaningful results. Gaps of knowledge can be bridged through the understanding metabolomics provides, which could lead to better targets, higher quality molecules, faster time to the clinic, and reduced risk and cost.”
Metabolomics has conducted thousands of metabolomics studies across numerous therapeutic areas and has developed expertise in metabolic pathways and targets that are involved in the onset of disease and its progression. Metabolon’s technology platforms are known for their rapid, repeatable results. Expert, credentialed biochemists interpret biologic data to provide actionable understanding into key disease metabolic processes, drug action, and patient response.
Metabolomics is a rapidly evolving field of biochemical research and discovery focused on the measurement of small molecules involved in metabolism. Metabolon’s proprietary metabolomics technology maps these small molecule pathways to identify diseases, discover biomarkers, and better understand complex biologic processes. The company’s business uses its metabolomics technology to conduct sponsored studies for life sciences researchers in industry and academia, which provide clues into complex biochemical processes. Data from these studies are used to populate Metabolon’s large and growing metabolomic information and pathway knowledge databases, which generate new product concepts for the company’s diagnostics business.
Related Links:
Metabolon
GlaxoSmithKline
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples